Data / Form D filings / Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc.: Form D filings
Oncternal Therapeutics, Inc., a biotechnology company in San Diego, CA, filed 9 Form D notices with the SEC between 2014 and 2020. The latest, on December 22, 2020, reports $6.5 million sold of a $6.5 million offering to 4 investors.
Find out what Oncternal Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 12230 El Camino Real, Suite 300, San Diego, CA, 92130
- Phone
- (858) 434-1113
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1260990
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 22, 2020 | New notice | $6,467,063 | $6,467,063 | $0 | 4 | Dec 14, 2020 | sec.gov |
| Nov 24, 2020 | New notice | $1,687,501 | $1,687,501 | $0 | 4 | Nov 20, 2020 | sec.gov |
| Sep 9, 2020 | New notice | $382,549 | $382,549 | $0 | 4 | Sep 1, 2020 | sec.gov |
| Aug 3, 2020 | New notice | $3,456,308 | $3,456,308 | $0 | 12 | Jul 17, 2020 | sec.gov |
| Jun 3, 2020 | New notice | $2,814,260 | $2,814,260 | $0 | 7 | May 19, 2020 | sec.gov |
| Oct 12, 2017 | New notice | $78,175,657 | $48,499,965 | $29,675,692 | 8 | Sep 29, 2017 | sec.gov |
| Nov 24, 2014 | New notice | $43,410,000 | $43,410,000 | $0 | 9 | Nov 14, 2014 | sec.gov |
| Mar 7, 2014 | Amendment | $21,272,455 | $21,272,455 | $0 | 2 | Mar 6, 2014 | sec.gov |
| Mar 6, 2014 | New notice | $21,272,455 | $21,272,455 | $0 | 2 | Mar 6, 2014 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| William R. LaRue | Director | |
| Xin R. Nakanishi, Ph.D. | Director | |
| Charles R. Theuer | Director | |
| Robert R. Wills, Ph.D. | Director | |
| Man R. Cho | Director | |
| James B. Breitmeyer, M.D., Ph.D. | Director, Executive Officer | |
| Richard B. Vincent | Executive Officer | |
| Igor B. Bilinsky, Ph.D. | Executive Officer | |
| Frank B. Hsu, M.D. | Executive Officer | |
| Gunnar F. Kaufmann | Executive Officer | |
| David F. Hale | Director | |
| Michael G. Carter, M.D., ChB, FRCP | Director | |
| Daniel G. Kisner, M.D. | Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
- Tempest Therapeutics, Inc. $7.5 million · Oct 14, 2026
- Lionheart Health, Inc. $387,500 · Oct 7, 2026
- Rakuten Medical, Inc. $9 million · Oct 6, 2026
- Zonaliz, Inc. $2.5 million · Oct 5, 2026
- Altay Therapeutics, Inc. $15.7 million · Oct 2, 2026
- Sialia Therapeutics, Inc. $1.5 million · Sep 29, 2026
- Vetmab Biosciences, Inc. $11.4 million · Sep 29, 2026
Every Form D from the week of Dec 21, 2020 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Oncternal Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.